Core Viewpoint - The company, Huajian Medical, has proposed a dual primary listing on the NASDAQ stock market through the issuance of new ordinary shares in the form of American Depositary Shares, with a confidential F-1 registration statement submitted to the SEC on September 29, 2025. This move is part of the company's global strategic layout and is expected to bring multiple positive impacts. Group 1: Strategic Impacts - Expanding global financing channels: Entering one of the largest and most comprehensive capital markets globally is expected to attract more long-term international investors focused on biotechnology and healthcare, providing strong capital support for future R&D and commercialization [1] - Enhancing international brand influence: Listing on NASDAQ will further enhance the company's corporate image and industry recognition in international markets, increasing opportunities for communication and collaboration with global partners, clients, and regulatory bodies [1] - Increasing share liquidity and valuation potential: Establishing a cross-market trading mechanism will help expand the investor base, improve overall share liquidity, and reflect the company's long-term value in a more international pricing environment [1] - Optimizing corporate governance and transparency: Adhering to U.S. securities regulations and disclosure requirements will enhance the company's governance standards and operational transparency, strengthening its compliance image and investor trust globally [1] Group 2: Future Strategic Flexibility - Providing flexibility for future strategic advancement: The dual listing structure offers a richer capital operation platform and strategic options for potential international cooperation, mergers, and business expansion [2]
华检医疗(01931)就建议于美国双重上市保密提交F-1表格登记声明草案